XML 72 R31.htm IDEA: XBRL DOCUMENT
v3.19.3

Summary of Significant Accounting Policies and Select Balance Sheet Information - Additional Information (Detail) - USD ($) shares in Millions | 3 Months Ended | 9 Months Ended | 12 Months Ended |
--- | --- | --- | --- | ---
Sep. 30, 2019 | Jun. 30, 2019 | Mar. 31, 2019 | Dec. 31, 2018 | Sep. 30, 2018 | Jun. 30, 2018 | Mar. 31, 2018 | Dec. 31, 2017 | Sep. 30, 2018 | Sep. 30, 2019 | Sep. 30, 2018 | Sep. 30, 2017 | Sep. 30, 2013 | Sep. 30, 2006 | Oct. 01, 2019
Summary Of Significant Accounting Policies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Net unrealized loss reclassified out of accumulated other comprehensive income (loss) with a corresponding adjustment to other income (loss) |  |  |  |  |  |  |  |  |  | $ 0 | $ 0 | $ 0 |  |  |
Held-to-maturity debt securities | $ 0 |  |  |  | $ 0 |  |  |  | $ 0 | 0 | 0 |  |  |  |
Realized gains or losses on sales of available-for-sale securities |  |  |  |  |  |  |  |  |  | 0 | 0 | 0 |  |  |
Depreciation expense |  |  |  |  |  |  |  |  |  | 4,700,000 | 3,700,000 | 3,000,000 |  |  |
Amortization expense |  |  |  |  |  |  |  |  | 2,700,000 | 2,600,000 |  | 2,600,000 |  |  |
Impairment loss |  |  |  |  |  |  |  |  |  |  | 0 |  |  |  |
Other impairment losses |  |  |  |  |  |  |  |  |  | 0 |  | 0 |  |  |
Goodwill impairment charges |  |  |  |  |  |  |  |  |  | 0 | 0 | 0 |  |  |
Goodwill | 26,171,000 |  |  |  | 27,032,000 |  |  |  | 27,032,000 | 26,171,000 | 27,032,000 | 27,282,000 |  |  |
Goodwill subject to revaluation due to fluctuations in exchange rates | 13,400,000 |  |  |  |  |  |  |  |  | 13,400,000 |  |  |  |  |
Impairment charges relating to long-lived assets |  |  |  |  |  |  |  |  |  | $ 0 | $ 0 | $ 0 |  |  |
Sales-based and minimum royalties due period |  |  |  |  |  |  |  |  |  | 45 days |  |  |  |  |
Weighted average diluted shares outstanding excluded outstanding stock options |  |  |  |  |  |  |  |  |  | 0.2 | 1.0 | 0.2 |  |  |
Revenue | 30,816,000 | $ 24,344,000 | $ 22,676,000 | $ 22,241,000 | 23,038,000 | $ 22,227,000 | $ 19,058,000 | $ 17,013,000 |  | $ 100,077,000 | $ 81,336,000 | $ 73,112,000 |  |  |
Income tax benefit |  |  |  |  |  |  |  |  |  | (34,000) | $ (3,075,000) | $ 3,107,000 |  |  |
Deferred rent liability | 1,200,000 |  |  |  |  |  |  |  |  | 1,200,000 |  |  |  |  |
ASC Topic 842 [Member] | Scenario Forecast [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Summary Of Significant Accounting Policies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Right of use asset |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 1,700,000
Lease obligation liability |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 2,900,000
Impact of Adoption [Member] | Adoption of ASC Topic 606 [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Summary Of Significant Accounting Policies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue |  |  |  |  |  |  |  |  |  | $ 1,300,000 |  |  |  |  |
Type of Revenue [Extensible List] |  |  |  |  |  |  |  |  |  | us-gaap:RoyaltyMember |  |  |  |  |
Customer Concentration Risk [Member] | Revenue [Member] | Abbott [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Summary Of Significant Accounting Policies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Percentage of revenue |  |  |  |  |  |  |  |  |  | 19.00% | 11.00% |  |  |  |
Customer Concentration Risk [Member] | Revenue [Member] | Medtronic [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Summary Of Significant Accounting Policies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Percentage of revenue |  |  |  |  |  |  |  |  |  | 14.00% | 16.00% | 18.00% |  |  |
SurVeil DCB [Member] | Product Concentration Risk | Revenue [Member] | Abbott [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Summary Of Significant Accounting Policies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Percentage of revenue |  |  |  |  |  |  |  |  |  | 13.00% | 5.00% | 0.00% |  |  |
Abbott [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Summary Of Significant Accounting Policies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Upfront fee received |  |  |  |  |  |  |  |  |  | $ 25,000,000 | $ 25,000,000 |  |  |  |
Collaborative arrangement milestone payment received |  |  |  |  |  |  |  |  |  | 10,000,000 |  |  |  |  |
Abbott [Member] | TRANSCEND Clinical Trial [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Summary Of Significant Accounting Policies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative arrangement milestone payment received |  |  |  |  |  |  |  |  |  | $ 10,000,000 |  |  |  |  |
Abbott [Member] | SurVeil DCB [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Summary Of Significant Accounting Policies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Clinical study completion period |  |  |  |  |  |  |  |  |  | 6 years |  |  |  |  |
IDA [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Summary Of Significant Accounting Policies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Reimbursement recorded as reduction to R&D expense |  |  |  |  |  |  |  |  |  | $ 700,000 | 800,000 | $ 800,000 |  |  |
Research and development [Member] | In-Process Research and Development [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Summary Of Significant Accounting Policies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Impairment loss |  |  |  |  |  |  |  |  |  | 300,000 |  | 300,000 |  |  |
Selling, General and Administrative Expenses [Member] | In-Process Research and Development [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Summary Of Significant Accounting Policies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Impairment loss |  |  |  |  |  |  |  |  |  |  |  | 100,000 |  |  |
ViaCyte, Inc. [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Summary Of Significant Accounting Policies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Equity method investment |  |  |  |  | 5,300,000 |  |  |  | 5,300,000 |  | 5,300,000 |  |  |  |
Impairment loss on investment |  |  |  |  |  |  |  |  |  |  |  |  | $ 100,000 | $ 4,700,000 |
Cost method of investment |  |  |  |  | $ 500,000 |  |  |  | $ 500,000 |  | 500,000 |  |  |  |
Maximum [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Summary Of Significant Accounting Policies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue recognized from activity with companies in which it had strategic investment |  |  |  |  |  |  |  |  |  | $ 100,000 | $ 100,000 | $ 100,000 |  |  |
Product sales payment terms |  |  |  |  |  |  |  |  |  | 45 days |  |  |  |  |
Payment period set for R&D services |  |  |  |  |  |  |  |  |  | 45 days |  |  |  |  |
Maximum [Member] | Impact of Adoption [Member] | Adoption of ASC Topic 606 [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Summary Of Significant Accounting Policies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Income tax benefit |  |  |  |  |  |  |  |  |  | $ 300,000 |  |  |  |  |
Maximum [Member] | Customer Concentration Risk [Member] | Revenue [Member] | Medtronic [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Summary Of Significant Accounting Policies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Percentage of revenue |  |  |  |  |  |  |  |  |  | 10.00% |  |  |  |  |
Maximum [Member] | Product Concentration Risk | Revenue [Member] | Medtronic [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Summary Of Significant Accounting Policies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Percentage of revenue |  |  |  |  |  |  |  |  |  | 3.00% |  |  |  |  |
Maximum [Member] | Abbott [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Summary Of Significant Accounting Policies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative arrangement additional potential milestone payments receivable | $ 57,000,000 |  |  |  |  |  |  |  |  | $ 57,000,000 |  |  |  |  |
Maximum [Member] | ViaCyte, Inc. [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Summary Of Significant Accounting Policies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Company's ownership percentage | 1.00% |  |  |  |  |  |  |  |  | 1.00% |  |  |  |  |
Minimum [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Summary Of Significant Accounting Policies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Product sales payment terms |  |  |  |  |  |  |  |  |  | 30 days |  |  |  |  |
Payment period set for R&D services |  |  |  |  |  |  |  |  |  | 30 days |  |  |  |  |
Leasehold Improvements [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Summary Of Significant Accounting Policies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Amortization period |  |  |  |  |  |  |  |  |  | Leasehold improvements are amortized over the shorter of the term of the lease or the estimated useful life of the asset. |  |  |  |  |

X
- Definition Clinical study completion period. + References No definition available. + Details
Name: | srdx_ClinicalStudyCompletionPeriod
Namespace Prefix: | srdx_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Collaborative arrangement additional potential milestone payments receivable. + References No definition available. + Details
Name: | srdx_CollaborativeArrangementAdditionalPotentialMilestonePaymentsReceivable
Namespace Prefix: | srdx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Collaborative arrangement milestone payment received. + References No definition available. + Details
Name: | srdx_CollaborativeArrangementMilestonePaymentReceived
Namespace Prefix: | srdx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Company ownership percentage of a cost method investment, which includes strategic investments. + References No definition available. + Details
Name: | srdx_CostMethodInvestmentOwnershipPercentage
Namespace Prefix: | srdx_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Generally the minimum payment terms for products sold to customers. + References No definition available. + Details
Name: | srdx_CreditSaleRecoveryGeneralPeriod
Namespace Prefix: | srdx_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Goodwill subject to revaluation due to fluctuations in exchange rates. + References No definition available. + Details
Name: | srdx_GoodwillSubjectToRevaluationDueToFluctuationsInExchangeRates
Namespace Prefix: | srdx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Impairment losses of intangible assets indefinite lived excluding goodwill, other. + References No definition available. + Details
Name: | srdx_ImpairmentLossesOfIntangibleAssetsIndefiniteLivedExcludingGoodwillOther
Namespace Prefix: | srdx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Revenue recognized from activity with companies in which we have a strategic investment. + References No definition available. + Details
Name: | srdx_RecognizedRevenue
Namespace Prefix: | srdx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Reimbursements for research and development expenditure. + References No definition available. + Details
Name: | srdx_ReimbursementsForResearchAndDevelopmentExpenditure
Namespace Prefix: | srdx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Research and development payment period. + References No definition available. + Details
Name: | srdx_ResearchAndDevelopmentPaymentPeriod
Namespace Prefix: | srdx_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Sales-based and minimum royalties due period. + References No definition available. + Details
Name: | srdx_SalesBasedAndMinimumRoyaltiesDuePeriod
Namespace Prefix: | srdx_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Summary of significant accounting policies. + References No definition available. + Details
Name: | srdx_SummaryOfSignificantAccountingPoliciesLineItems
Namespace Prefix: | srdx_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Upfront fee received. + References No definition available. + Details
Name: | srdx_UpfrontFeeReceived
Namespace Prefix: | srdx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 2 -Subparagraph (a)(2) -URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 45 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274 + Details
Name: | us-gaap_AmortizationOfIntangibleAssets
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257 + Details
Name: | us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 45 -Paragraph 4 -URI http://asc.fasb.org/extlink&oid=109226348&loc=d3e2420-110228 + Details
Name: | us-gaap_AssetImpairmentCharges
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition This item represents the difference between the gross realized gains and losses realized on the sale of debt or equity securities categorized neither as held-to-maturity nor trading securities. Additionally, this item would include any losses recognized for other than temporary impairments (OTTI) of the subject investments in debt and equity securities. + References No definition available. + Details
Name: | us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossNet
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 18 -URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 20 -URI http://asc.fasb.org/extlink&oid=118260190&loc=d3e13531-108611 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 21 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=118260190&loc=d3e13537-108611 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 20 -URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592 + Details
Name: | us-gaap_ConcentrationRiskPercentage1
Namespace Prefix: | us-gaap_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount, after adjustment, of cost-method investment. Adjustments include, but are not limited to, dividends received in excess of earnings after date of investment that are considered a return of investment and other than temporary impairments. + References No definition available. + Details
Name: | us-gaap_CostMethodInvestments
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition For a classified balance sheet, the cumulative difference between the rental income or payments required by a lease agreement and the rental income or expense recognized on a straight-line basis, or other systematic and rational basis more representative of the time pattern in which use or benefit is granted or derived from the leased property, expected to be recognized in income or expense, by the lessor or lessee, respectively, more than one year after the balance sheet date. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.26(c)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 840 -SubTopic 20 -Section 25 -Paragraph 2 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=77902458&loc=d3e39927-112707 + Details
Name: | us-gaap_DeferredRentCreditNoncurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585 + Details
Name: | us-gaap_Depreciation
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition This item represents an other than temporary decline in value that has been recognized against an investment accounted for under the equity method of accounting. The excess of the carrying amount over the fair value of the investment represents the amount of the write down which is or was reflected in earnings. The written down value is a new cost basis with the adjusted value of the investment becoming its new carrying value subject to the equity accounting method. Evidence of a loss in value might include, but would not necessarily be limited to, absence of an ability to recover the carrying amount of the investment or inability of the investee to sustain an earnings capacity which would justify the carrying amount of the investment. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 323 -SubTopic 10 -Section 35 -Paragraph 32 -URI http://asc.fasb.org/extlink&oid=118954474&loc=d3e32787-111569 + Details
Name: | us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 323 -SubTopic 10 -Section 45 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 25 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8813-108599 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.12) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 + Details
Name: | us-gaap_EquityMethodInvestments
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Present value of lessee's discounted obligation for lease payments from finance lease. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 842 -SubTopic 20 -Section 50 -Paragraph 6 -URI http://asc.fasb.org/extlink&oid=77888426&loc=SL77918701-209980 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 842 -SubTopic 20 -Section 45 -Paragraph 1 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977 + Details
Name: | us-gaap_FinanceLeaseLiability
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of lessee's right to use underlying asset under finance lease. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 842 -SubTopic 20 -Section 45 -Paragraph 1 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977 + Details
Name: | us-gaap_FinanceLeaseRightOfUseAsset
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 20 -Section 45 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=77989000&loc=SL49117168-202975 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 20 -Section 45 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266 + Details
Name: | us-gaap_Goodwill
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 20 -Section 50 -Paragraph 2 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=108376223&loc=d3e13854-109267 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (e) -URI http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 20 -Section 45 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=99380562&loc=d3e13777-109266 + Details
Name: | us-gaap_GoodwillImpairmentLoss
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of investment in debt security measured at amortized cost (held-to-maturity). + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 320 -SubTopic 10 -Section 45 -Paragraph 1 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=118954083&loc=d3e26610-111562 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 320 -SubTopic 10 -Section 50 -Paragraph 5 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=118939692&loc=d3e27232-111563 + Details
Name: | us-gaap_HeldToMaturitySecurities
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 3 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585 + Details
Name: | us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (h) -URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)) -URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 20 -Section 45 -Paragraph 2 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=109238882&loc=d3e38679-109324 + Details
Name: | us-gaap_IncomeTaxExpenseBenefit
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The amount of other than temporary impairment losses on investments in debt and equity securities categorized as Available-for-sale which have been recognized in earnings during the period. Such impairment losses consist of other than temporary impairments (OTTI) on equity securities, credit losses on investments in debt securities, and when the entity intends to sell an impaired debt security or it is more likely than not that the entity will be required to sell the impaired debt security before recovery of its amortized cost basis. + References No definition available. + Details
Name: | us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNetAvailableforsaleSecurities
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Describes the periods of time over which an entity anticipates to receive utility from its property, plant and equipment (that is, the periods of time over which an entity allocates the initial cost of its property, plant and equipment). + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 35 -Paragraph 4 -URI http://asc.fasb.org/extlink&oid=68071081&loc=d3e1205-110223 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790 + Details
Name: | us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 4 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130543-203045 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130545-203045 + Details
Name: | us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Indicates type of revenue from product and service. Includes, but is not limited to, revenue from contract with customer and other sources. + References No definition available. + Details
Name: | us-gaap_TypeOfRevenueExtensibleList
Namespace Prefix: | us-gaap_
Data Type: | srt-types:extensibleListItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementScenarioAxis=srt_ScenarioForecastMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis=us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201409Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueSegmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_MajorCustomersAxis=srdx_AbbottMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_MajorCustomersAxis=srdx_MedtronicMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=srdx_SurVeilDrugCoatedBalloonMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ConcentrationRiskByTypeAxis=us-gaap_ProductConcentrationRiskMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=srdx_AbbottMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=srdx_TranscendClinicalTrialMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=srdx_IndustrialDevelopmentAgencyOfIrelandMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srdx_ViaCyteIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |